This 10-K/A amendment provides the previously omitted information required by Items 10 through 14 of Part III of the original 2025 Form 10-K. The filing includes details on the board of directors, executive compensation, security ownership, and related party transactions. Soleno reported 2025 net revenue of $190.4 million from VYKAT XR. The company achieved positive net income of $20.9 million for the 2025 fiscal year. Soleno entered into a definitive merger agreement with Neurocrine Biosciences on April 5, 2026, for $53.00 per share in cash.